Known benefits and unknown risks of active surveillance of cervical intraepithelial neoplasia grade 2
KD Lycke, LK Petersen, PE Gravitt… - Obstetrics & …, 2022 - journals.lww.com
Financial Disclosure Anne Hammer has received a speaker's fee from AstraZeneca,
Denmark, and has received reagents at reduced cost from Roche Diagnostics, Denmark …
Denmark, and has received reagents at reduced cost from Roche Diagnostics, Denmark …
Performance of HPV E4 and p16INK4a biomarkers in predicting regression of cervical intraepithelial neoplasia grade 2 (CIN2): protocol for a historical cohort study
RK Damgaard, D Jenkins, MN De Koning… - BMJ open, 2022 - bmjopen.bmj.com
Introduction Cervical intraepithelial neoplasia grade 2 (CIN2) represents a spectrum of
lesions with variable progression and regression. Pathological diagnosis of CIN2 is …
lesions with variable progression and regression. Pathological diagnosis of CIN2 is …
“I feel reassured, but there is no guarantee.” How do women with a future childbearing desire respond to active surveillance of cervical intraepithelial neoplasia grade …
J Hansen, P Kirkegaard, B Folmann… - Acta Obstetricia et …, 2022 - Wiley Online Library
Abstract Introduction In Denmark, women with a future childbearing desire diagnosed with
cervical intraepithelial neoplasia grade 2 (CIN2) are recommended active surveillance …
cervical intraepithelial neoplasia grade 2 (CIN2) are recommended active surveillance …
[HTML][HTML] Цервикальные интраэпиталиальные неоплазии II степени: эффективность противовирусной терапии
ОП Виноградова, НА Андреева, ОИ Артёмова… - Доктор. Ру, 2022 - cyberleninka.ru
Цель исследования: оценка эффективности применения противовирусного препарата
при лечении ВПЧ-ассоциированной цервикальной интраэпителиальной неоплазии …
при лечении ВПЧ-ассоциированной цервикальной интраэпителиальной неоплазии …